Far Infrared Irradiation for Stroke Rehabilitation
|ClinicalTrials.gov Identifier: NCT00675155|
Recruitment Status : Unknown
Verified January 2009 by GAAD Medical Research Institute Inc..
Recruitment status was: Active, not recruiting
First Posted : May 8, 2008
Last Update Posted : January 5, 2009
|Condition or disease||Intervention/treatment||Phase|
|Stroke||Radiation: Far Infrared Radiation||Phase 1|
A stroke is a sudden loss of brain function. The interruption of blood flow or the rupture of blood vessels causes brain cells (neurons) in the affected area to die. The effects of a stroke depend on where the brain was injured, as well as how much damage occurred. A stroke can impact any number of areas including your ability to move, see, remember, speak, reason and read and write.
It is hereby postulated that irradiation using far infrared, with wavelength between 5 to 20 microns, of the central nervous system, the endocrine system and the whole body could prevent, control, manage or possibly lead to complete rehabilitation of people with stroke.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||10 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase 1 Study to Determine the Efficacy of Using Far Infrared Radiation for Stroke Rehabilitation|
|Study Start Date :||May 2008|
|Estimated Primary Completion Date :||May 2010|
|Estimated Study Completion Date :||June 2010|
Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
Radiation: Far Infrared Radiation
Radiation: Far Infrared Radiation (5μm to 20μm wavelength) Far Infrared radiation for 30 to 40 minutes per treatment session.
- Management and Cure of Stroke [ Time Frame: 2 Years ]
- Rehabilitation of the following: ability to move, see, remember, speak, reason and read and write. [ Time Frame: 2 Years ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00675155
|The Centre for Incurable Diseases|
|Toronto, Ontario, Canada, M4V 1L5|
|Principal Investigator:||Ken Nedd, M.D.||GAAD Medical Research Institute Inc.|